In summary, we developed a new HCC gene therapeutic strategy with high cancer-selectivity, the least targeting of normal cells, and efficient anticancer effects, based on the targeted replacement of TERT RNA through a trans-splicing ribozyme under control of liver-specific miR-122a expression. The gene discussed is TERT; the disease is hepatocellular carcinoma.